Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: C-peptide


How low is really low? Comparison of two C-peptide assays to establish residual C-peptide production in type 1 diabetes

January 6th 2022

The IRMA provided the lowest threshold for quantification of serum C-peptide. LoQ of commercially available assays should be established in-house before applying them in research studies and clinical trials in which low C-peptide levels have clinical or scientific relevance (Diabetic Medicine)

Categories: Monitoring, News
Tags: C-peptide, Type 1 Diabetes

Categories: Monitoring
Tags: C-peptide, Type 1 Diabetes

Reappearance of C-Peptide During the Third Trimester of Pregnancy in Type 1 Diabetes: Pancreatic Regeneration or Fetal Hyperinsulinism?

August 12th 2021

First maternal C-peptide appearance at 34 weeks was associated with midtrimester hyperglycemia, elevated cord blood C-peptide, and high rates of neonatal complications. This suggests transfer of C-peptide from fetal to maternal serum and is inconsistent with pregnancy-related β-cell regeneration (Diabetes Care)

Categories: Gestational, News
Tags: C-peptide, hyperglycemia, Type 1 Diabetes

Categories: Gestational
Tags: C-peptide, hyperglycemia, Type 1 Diabetes

Exenatide ER in patients with Type 1 diabetes with and without residual insulin production

June 24th 2020

Treatment with exenatide ER may have short‐term benefits in some individuals with T1D who are overweight or with detectable levels of C‐peptide, but short term improvements were not sustained (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: C-peptide, exantide, Type 1 Diabetes

Categories: Medication
Tags: C-peptide, exantide, Type 1 Diabetes

Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide

January 6th 2019

The glucagon response to an MMTT in people with long-standing type 1 diabetes is not reduced by the presence of residual beta cells. The reduction of GLP-1 responses according to residual C-peptide levels suggests specific regulatory pathways (Diabetologia)

Categories: News, Pathology
Tags: C-peptide, GLP-1, Type 1 Diabetes

Categories: Pathology
Tags: C-peptide, GLP-1, Type 1 Diabetes

C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase

June 24th 2018

These data support two clear phases of C-peptide decline: an initial exponential fall over a 7-year period, followed by a prolonged stabilization where C-peptide levels no longer decline. Understanding the pathophysiological and immunological differences between these two phases will give crucial insights into understanding β-cell survival (Diabetes Care)

Categories: News, Pathology
Tags: C-peptide, Type 1 Diabetes

Categories: Pathology
Tags: C-peptide, Type 1 Diabetes

Metabolic risk profiles in diabetes stratified according to age at onset, islet autoimmunity and fasting C-peptide

October 5th 2017

Our results demonstrate that fasting C-peptide and GADab status, but not age at onset, define groups of patients with diabetes with clinically relevant differences in glycaemic control and cardiometabolic risk (Diabetes Research and Clinical Practice)

Categories: News, Screening
Tags: C-peptide, GAS

Categories: Screening
Tags: C-peptide, GAS

A Practical Review of C-Peptide Testing in Diabetes

May 9th 2017

We explore the potential uses of c-peptide measurement in clinical practice (Diabetes Therapy)

Categories: Monitoring, News
Tags: C-peptide

Categories: Monitoring
Tags: C-peptide

C-peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry

May 6th 2015

In youth with T2D, a decline in C-peptide is associated with deterioration of metabolic control and the need for insulin treatment. C-peptide levels decrease over time. However, even insulin-treated patients with 6 or more years of T2D and elevated HbA1c levels retain substantial endogenous insulin secretion (Pediatric Diabetes)

Categories: News, Pathology
Tags: C-peptide, Type 2 Diabetes

Categories: Pathology
Tags: C-peptide, Type 2 Diabetes

Urinary C-Peptide/Creatinine Ratio Can Distinguish Maturity-Onset Diabetes of the Young from Type 1 Diabetes in Children and Adolescents

April 2nd 2015

We showed that the UCPCR and fasting C-peptide levels in children and adolescents can distinguish patients with MODY from patients with T1DM with high specificity and sensitivity (Hormone Research in Paediatrics)

Categories: News, Screening
Tags: C-peptide, creatinine, MODY

Categories: Screening
Tags: C-peptide, creatinine, MODY

Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD

February 25th 2015

C-peptide and islet autoantibodies may serve as biomarkers to predict the risk of severe hypoglycaemia during intensification of type 2 diabetes treatment (Diabetologia)

Categories: Monitoring, News
Tags: autoantibodies, biomarkers, C-peptide

Categories: Monitoring
Tags: autoantibodies, biomarkers, C-peptide

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaNapp DiabetesBoehringer IngelheimNovo Nordisk

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)About Ascensia Diabetes CareAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership